Hier finden Sie grundlegende Angaben zu klinischen Studien des Comprehensice Cancer Centers Mainfranken (CCC MF)
Filter aktiv
Seite 1 - Studien 1 bis 4 von insgesamt 4
- Rekrutierung läuftAdvancing Brigatinib Properties in anaplastic lymphoma kinase positive non-small cell lung cancer (ALK+ NSCLC) patients by deep phenotypingMolekulare Marker
- Rekrutierung läuftFirst Line Ipilimumab+Nivolumab Combined with two cycles of Chemotherapy in NSCLC [FINN]
- Rekrutierung läuftAn open-Label, multi-Center, Phase IV, roll-over study in patients with ALK positive malignancies who have completed a prior Novartis-sponsored ceritinib (LDK378) study and are judged by the investigator to benefit from continued Treatment with ceritinibMolekulare Marker
- Rekrutierung läuftEfficacy Comparison of Dostarlimab Plus Chemotherapy vs Pembrolizumab plus Chemotherapy in Participants with metatstatic non-squamous non-small Cell Lung